Palomino Laboratories (PALX) director adds 12,500 shares at $4

Rhea-AI Filing Summary

Palomino Laboratories Inc. director and secretary Richard Ogawa made an open-market purchase of the company’s Common Stock. He bought 12,500 shares at $4.00 per share, increasing his direct holdings to 1,762,500 shares. This filing shows a modest increase in his personal investment stake.

Insider Trade Summary

Net Buyer: 12,500 shares ($50,000)

Net Buy 1 txn

Insider Ogawa Richard

Role Secretary

Bought 12,500 shs ($50K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	12,500	$4.00	$50K

Holdings After Transaction: Common Stock — 1,762,500 shares (Direct, null)

Footnotes (1)

Key Figures

Shares purchased: 12,500 shares Purchase price: $4.00 per share Total shares after transaction: 1,762,500 shares +1 more

4 metrics

Shares purchased 12,500 shares Open-market purchase on April 20, 2026

Purchase price $4.00 per share Price paid for Common Stock

Total shares after transaction 1,762,500 shares Direct holdings following the purchase

Net buy shares 12,500 shares Net change in reported position from this filing

Key Terms

Common Stock, open-market purchase, Form 4

3 terms

Common Stock financial

"The security involved in the transaction is listed as Common Stock."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

open-market purchase financial

"The transaction_action field describes this as an open-market purchase."

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Form 4 regulatory

"This insider transaction is disclosed through a Form 4 filing."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ogawa Richard

(Last) (First) (Middle)

313 BRYANT COURT

(Street)

PALO ALTO, CALIFORNIA 94301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Palomino Laboratories Inc. [ NONE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Secretary

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/20/2026		P		12,500	A	$4	1,762,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Richard Ogawa	04/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Palomino Laboratories (PALX) report?

Palomino Laboratories reported that director and secretary Richard Ogawa made an open-market purchase of the company’s Common Stock. He acquired 12,500 shares at $4.00 per share, increasing his direct ownership position as disclosed in this Form 4 filing.

How many Palomino Laboratories (PALX) shares did Richard Ogawa buy?

Richard Ogawa bought 12,500 shares of Palomino Laboratories Common Stock. The transaction was an open-market purchase at $4.00 per share, as reported in the insider trading disclosure, and modestly raised his overall direct shareholdings in the company.

At what price were the Palomino Laboratories (PALX) shares purchased?

The Palomino Laboratories shares were purchased at $4.00 per share. This price applied to all 12,500 Common Stock shares acquired in the open-market transaction, according to the Form 4, and reflects the cost basis for this specific insider buy.

What is Richard Ogawa’s total Palomino Laboratories (PALX) holding after the trade?

After the trade, Richard Ogawa directly holds 1,762,500 shares of Palomino Laboratories Common Stock. This total includes the newly purchased 12,500 shares and represents his reported direct ownership following the disclosed open-market transaction.

Was the Palomino Laboratories (PALX) insider trade a buy or a sell?

The Palomino Laboratories insider trade was a buy. Director and secretary Richard Ogawa executed an open-market purchase of 12,500 Common Stock shares, increasing his direct holdings, rather than selling or disposing of any shares in this particular filing.